Skip to main content

Table 3 Treatment in the C and F group*

From: Adefovir dipivoxil induced hypophosphatemic osteomalacia in chronic hepatitis B: a comparative study of Chinese and foreign case series

Treatment

Presence

Absence

Df

P value

cADV#

  

1

0.017b

 C

81(89.0%)

10(11.0%)

 F

19(67.9%)

9(32.1%)

rADV

  

1

0.001b

 C

4(4.4%)

87(95.6%)

 F

8(28.6%)

20(71.4%)

ETV

  

1

0.060a

 C

51(56.0%)

40(44.0%)

 F

10(35.7%)

18(64.3%)

Phos.

  

1

0.210a

 C

53(58.2%)

38(41.8%)

 F

20(71.4%)

8(28.6%)

Calcium

  

1

0.001a

 C

47(51.6%)

44(48.4%)

 F

3 (10.7%)

25(89.3%)

Calcitriol

  

1

0.185a

 C

52(57.1%)

39(42.9%)

 F

12(42.9%)

16(57.1%)

BM

  

1

0.755b

 C

6(6.6%)

85(93.4%)

 F

3(10.7%)

25(89.3%)

  1. *Ninety-one and 28 patients had treatment in the C and F group, respectively
  2. cADV ceased Adefovir Dipivoxil, rADV reduced Adefovir Dipivoxil, ETV entecavir, Phos. Phosphate supplement, Calcium Calcium supplement, Calcitriol Calcitriol supplement, BM drugs regulating bone metabolism
  3. a Pearson Chi-square test
  4. bCorrected Pearson Chi-square test